Bedrijfsoverzicht
USANA Health Sciences, Inc. is a prominent entity within the consumer defensive sector, specifically operating in the packaged foods industry, where it develops, manufactures, and sells science-based nutritional, personal care, and skincare products across the Asia Pacific, the Americas, and Europe. The company organizes its operations into two distinct segments: Core nutritional and Hiya Direct-To-Consumer, allowing for a diversified approach to market penetration through different distribution channels. This entity maintains a substantial workforce of 1,570 employees and holds a market capitalization of $334.26 million, reflecting its established position as a mid-cap player in the global health and wellness market. With annual revenue reaching $925.26 million, the company demonstrates a significant scale that provides a buffer against economic fluctuations, characteristic of the defensive nature of its sector, while its market cap suggests a valuation that is currently modest relative to its total sales volume.
Financiële gezondheid
The financial performance of USANA Health Sciences, Inc. over the trailing twelve months reveals a revenue stream of $925.26 million, which generated a net income of $10.76 million and an EBITDA of $83.42 million. The substantial gap between the total revenue and the relatively low net income highlights a distinct cost structure where operating expenses, including cost of goods sold and administrative costs, consume the majority of top-line growth before reaching the bottom line. The company reports a free cash flow of $36.85 million, which indicates a positive cash generation capability that supports operational flexibility without relying on external financing or asset liquidation. Margin analysis shows a gross margin of 78.3%, suggesting high pricing power or efficient production relative to material costs, while the operating margin sits at 7.6% and the profit margin is 1.2%, indicating that significant overhead and selling expenses are required to maintain the direct-to-consumer and retail distribution networks. On the balance sheet, the company holds $158.38 million in cash against $31.96 million in debt, resulting in a conservative financial profile supported by a debt-to-equity ratio of 5.45, which warrants close monitoring given the high leverage relative to equity. Liquidity is further evidenced by a current ratio of 2.24, confirming that the company possesses more than double the current assets necessary to cover its short-term liabilities. Return on equity stands at 2.0% and return on assets at 4.3%, metrics that collectively reveal how management allocates capital and generates returns on the invested base, though the low ROE suggests that equity deployment efficiency is currently limited.
Waarderingsbeoordeling
Valuation metrics for USANA Health Sciences, Inc. present a complex picture with a trailing P/E ratio of 31.22 compared to a forward P/E of 6.54. This stark disparity between the historical and forward price-to-earnings multiples implies that the market is pricing in a dramatic shift in expected earnings trajectory, potentially anticipating a future where earnings growth will significantly outpace current levels or that current earnings are non-recurring. The price-to-book ratio is recorded at 0.62, indicating that the stock trades at a discount to its book value, which may reflect market skepticism regarding the quality of assets or the sustainability of future cash flows relative to historical book equity. Alternative valuation measures include a price-to-sales ratio of 0.36 and an EV/EBITDA of 3.13, both of which suggest the company is valued on a multiple of sales and earnings before interest, taxes, depreciation, and amortization that is significantly lower than the broader market averages, often seen in growth stocks with high reinvestment needs. Price action over the last year has seen the stock fluctuate between a 52-week high of $38.32 and a 52-week low of $16.60, placing the current trading price at a position that reflects significant volatility from its recent peaks. The stock exhibits a beta of 0.70, meaning its price volatility is less than the broader market, suggesting it may act as a defensive holding that moves with less intensity than the overall equity index during periods of market stress.
Growth & Income
Growth dynamics for the company show a revenue growth rate of 5.9% year-over-year, while earnings growth is marked as N/A in the available data. The absence of reported earnings growth figures alongside positive revenue expansion implies that the company is currently prioritizing top-line scale and market share acquisition over immediate profit per share growth, or that one-time charges are impacting the bottom line. As a non-dividend payer, USANA Health Sciences, Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all of its net income to reinvest into research and development, marketing, and operational expansion rather than distributing cash to shareholders. This reinvestment strategy is consistent with companies in the nutritional and personal care sectors that require continuous innovation to maintain competitive advantages in a science-based product landscape. The overall growth and income profile is characterized by moderate revenue expansion and a complete absence of dividend income, positioning the asset as a growth-oriented investment that relies on capital appreciation rather than yield for total return generation.